{"id":28081,"date":"2026-01-11T16:42:17","date_gmt":"2026-01-11T15:42:17","guid":{"rendered":"https:\/\/jegharkraeft.dk\/?p=28081"},"modified":"2026-01-11T21:08:28","modified_gmt":"2026-01-11T20:08:28","slug":"phesgo","status":"publish","type":"post","link":"https:\/\/jegharkraeft.dk\/en\/phesgo\/","title":{"rendered":"Phesgo ved kr\u00e6ft. HER2-positiv brystkr\u00e6ft, Pertuzumab, Trastuzumab, Subkutan kr\u00e6ftbehandling, Phesgo bivirkninger, Phesgo vs Herceptin, Perjeta og Herceptin, Indspr\u00f8jtning mod brystkr\u00e6ft, Bivirkninger ved Phesgo, Hjertesvigt ved brystkr\u00e6ftmedicin, Phesgo dosering,"},"content":{"rendered":"\n<div class=\"wp-block-group alignfull is-style-section-5 has-contrast-color has-base-background-color has-text-color has-background has-link-color wp-elements-cdad42ca69a2865a25fb8a9399e25ad3 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained is-style-section-5--2\" id=\"menu\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-ca2dd60b wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-7dcb782fe06e372bd968f4bf90d58c0a\"><span class=\"ez-toc-section\" id=\"Behandlinger\"><\/span><a href=\"https:\/\/jegharkraeft.dk\/kraeft-behandlinger\">Behandlinger <\/a><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-group has-custom-interne-links-color has-text-color has-link-color wp-elements-1dc737958b76cb0a6d2cc93df015fb61 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<h4 class=\"wp-block-heading has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-49b301964cbfab50924982081a6d1c63\"><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-kraeftbehandlinger-oversigt#traditionellebehandlingertekst\">Traditionelle Behandlinger Oversigt<\/a><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-kraeftbehandlinger-oversigt#traditionellebehandlingertekst\"><\/a><a href=\"https:\/\/jegharkraeft.dk\/alternative-oversigt\"><\/a><\/h4>\n\n\n\n<p class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-d07406a00d8f6420b2073bafbd0d05a6 wp-block-paragraph\"><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-behandlinger\">0. Traditionelle Behandlinger Alment<\/a><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-60aa910da5284a603c7fa5ea0e6431c9\"><a href=\"https:\/\/jegharkraeft.dk\/genterapi-tra-1\/\">Prim\u00e6re Behandlingsformer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-fc470c648162881ae48582717fdedf7d\"><a href=\"https:\/\/jegharkraeft.dk\/minimer-kemo\">Supportive Behandlinger<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-a7b1777caf915a9506b5da491c5ab820\"><a href=\"https:\/\/jegharkraeft.dk\/cyberknife\">Specifikke Behandlinger og teknikker<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-c636869deb007046657d11c8b2fb2f29\"><a href=\"https:\/\/jegharkraeft.dk\/genterapi-1\">S\u00e6rlige Kategorier<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/antimetabolitter-laegemidler\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">L\u00e6gemiddelbehandling<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-4a892c6cef3e7fe82f18a27de62f7b2e\"><a href=\"https:\/\/jegharkraeft.dk\/antimetabolitter-laegemidler\">5.A Kemoterapi<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-5ca910f8f6040db5d8927f0cc31cdb05\"><a href=\"https:\/\/jegharkraeft.dk\/hormonterapi-1\">5.B Hormonbehandling<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-bafac9b29b2e7081094b8ecdd106aa04\"><a href=\"https:\/\/jegharkraeft.dk\/car-t-behandling\">5.C Immun-onkologi<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/enhertu\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">5.D M\u00e5lrettet terapi<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-aff51506a13f56b4901ed8157c7879e4\"><a href=\"https:\/\/jegharkraeft.dk\/enhertu\">Enhertu<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-412dd074b9110f66a628338b243afc64\"><a href=\"https:\/\/jegharkraeft.dk\/enzalutamid\">Enzalutamid<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-0ce37051b51c5803e8778e4490c0cc3e\"><a href=\"https:\/\/jegharkraeft.dk\/monoklonale-antistoffer\">Monoklonale antistoffer<\/a><\/li>\n\n\n\n<li class=\"has-custom-her-st-r-du-color has-text-color has-link-color wp-elements-5aef07eda066df8fc475a9bac29f52be\"><a href=\"#phesgo\">Phesgo (scroll ned)<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-e9efc074566f4be021ee42e416810914\"><a href=\"https:\/\/jegharkraeft.dk\/trastuzumab-tdm1\">Trastuzumab (TDM1)<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-3a70af5916db95f672ef3cb5672a7029\"><a href=\"https:\/\/jegharkraeft.dk\/tyrosinkinasehaemmere\">Tyrosinkinaseh\u00e6mmere<\/a><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-8605df5e02ec23116b26075f98d31870\"><a href=\"https:\/\/jegharkraeft.dk\/angiogenesehaemmere\">5.E Andre pr\u00e6parater<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"705\" height=\"708\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7.jpg\" alt=\"Phesgo symboliseret ved et h\u00e6tteglas med p\u00e5skriften Phesgo og en spr\u00f8jte med kanyle p\u00e5 en metalbakke.\" class=\"wp-image-28097\" style=\"aspect-ratio:3\/2;object-fit:cover;width:550px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7.jpg 705w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7-600x603.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7-150x150.jpg 150w\" sizes=\"auto, (max-width: 705px) 100vw, 705px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-global-padding is-layout-constrained wp-container-core-group-is-layout-b040ace0 wp-block-group-is-layout-constrained has-background\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--20);padding-bottom:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--20);background-image:url(&apos;https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo7.jpg&apos;);background-size:cover;\">\n<div class=\"gb-element-906497af\">\n<h1 class=\"wp-block-heading\" id=\"phesgo\"><span class=\"ez-toc-section\" id=\"Phesgo_mod_kraeft\"><\/span>Phesgo mod kr\u00e6ft<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-sort-tekst-color has-alpha-channel-opacity has-custom-sort-tekst-background-color has-background\"\/>\n\n\n\n<h4 class=\"wp-block-heading\">Resum\u00e9 om Phesgo<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sammens\u00e6tning:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Phesgo er et kombinationspr\u00e6parat best\u00e5ende af to monoklonale antistoffer (pertuzumab og trastuzumab) samt enzymet vorhyaluronidase alfa. [7]<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Indikation:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Godkendt til behandling af HER2-positiv brystkr\u00e6ft i tidligt stadie (f\u00f8r\/ efter operation) samt ved metastatisk brystkr\u00e6ft (spredning).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Administration:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gives som subkutan injektion (under huden) i l\u00e5ret, hvilket erstatter to separate intraven\u00f8se infusioner.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ny viden:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Studier indikerer, at behandlingen i visse tilf\u00e6lde kan gives uden samtidig kemoterapi uden at forringe den samlede overlevelse, hvilket sk\u00e5ner patienten for toksiske bivirkninger. [4]<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-sort-tekst-color has-alpha-channel-opacity has-custom-sort-tekst-background-color has-background\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hvad_er_Phesgo\"><\/span>Hvad er Phesgo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-150x150.jpg\" alt=\"Phesgo syboliseret ved navne p\u00e5 de tre produkter det indeholder og derunder et h\u00e6tteglas med Phesgo.\" class=\"wp-image-28107\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo11.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\">M\u00e5lrettet<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Phesgo er et m\u00e5lrettet middel, der fungerer som en intelligent m\u00e5ls\u00f8gende robot. I mods\u00e6tning til traditionel kemoterapi, der angriber alle celler, der deler sig hurtigt, genkender Phesgo helt specifikt de HER2-proteiner, som sidder p\u00e5 kr\u00e6ftcellernes overflade. Det kobler sig p\u00e5 disse proteiner og blokerer de v\u00e6kstsignaler, som kr\u00e6ften er afh\u00e6ngig af for at overleve.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Kombination<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Pr\u00e6paratet samler de to antistoffer, <a href=\"https:\/\/jegharkraeft.dk\/monoklonale-antistoffer\/\">Perjeta<\/a> og <a href=\"https:\/\/jegharkraeft.dk\/monoklonale-antistoffer\/\">Herceptin<\/a>, i \u00e9n fast dosis. Hvor man tidligere gav disse som to separate dropposer i en vene (blod\u00e5re), gives Phesgo nu som en samlet indspr\u00f8jtning under huden.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Optages gennem bindev\u00e6v<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Det unikke ved Phesgo er tils\u00e6tningen af det tredje stof: Vorhyaluronidase alfa. Dette er et enzym, der midlertidigt nedbryder stoffet hyaluronan i underhudens bindev\u00e6v. Hyaluronan fungerer normalt som en &#8220;lim&#8221;, der holder v\u00e6vet fast. Ved at nedbryde det, \u00f8ges v\u00e6vets gennemtr\u00e6ngelighed drastisk, hvilket g\u00f8r det muligt at spr\u00f8jte en stor m\u00e6ngde v\u00e6ske (10-15 ml) ind under huden p\u00e5 kort tid, hvorefter det hurtigt optages i blodbanen. V\u00e6vet gendannes efterf\u00f8lgende fuldst\u00e6ndigt inden for 24-48 timer. [7]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hvordan_virker_det\"><\/span>Hvordan virker det<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-150x150.jpg\" alt=\"Phesgo symboliseret ved en pc med et billede af hvordan rosa kr\u00e6ftcelle bliver angrebet.\" class=\"wp-image-28098\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo6.jpg 852w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Behandlingen angriber kr\u00e6ftceller, der overudtrykker HER2-receptoren. HER2 er et protein p\u00e5 celleoverfladen, der fungerer som en &#8220;gaspedal&#8221; for cellev\u00e6kst. Phesgo leverer en s\u00e5kaldt dual blokade (dobbelt h\u00e6mning) af denne receptor:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Trastuzumab:<\/strong> Binder sig til dom\u00e6ne IV p\u00e5 HER2-receptoren. Dette h\u00e6mmer signalveje inde i cellen (PI3K\/AKT), der ellers sikrer celleoverlevelse, og markerer samtidig cellen til destruktion af immunforsvaret (ADCC). Konkret er dette hvad der sker:\n<ul class=\"wp-block-list\">\n<li>Medicinen s\u00e6tter sig p\u00e5 &#8220;antennen&#8221; (receptoren) uden p\u00e5 cellen.<\/li>\n\n\n\n<li>Dette sender et signal ind i cellen, som slukker for de motorer (signalveje), der holder cellen i live.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Pertuzumab:<\/strong> Binder sig til dom\u00e6ne II p\u00e5 HER2-receptoren. Dette er afg\u00f8rende, da det forhindrer HER2 i at parre sig med andre receptorer (is\u00e6r HER3). Denne &#8220;parring&#8221; (dimerisering) er den kraftigste v\u00e6kstsignal-mekanisme i kr\u00e6ftcellen.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Ved at blokere receptoren to forskellige steder samtidigt, opn\u00e5s en synergieffekt, hvor kr\u00e6ftcellens v\u00e6kstsignal slukkes mere effektivt, end hvis stofferne blev givet hver for sig. Slutresultatet er apoptose (programmeret celled\u00f8d).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sadan_foregar_behandlingen\"><\/span>S\u00e5dan foreg\u00e5r behandlingen<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-150x150.jpg\" alt=\"Phesgo symboliseret ved en kvindes blottede l\u00e5r og en behandsket h\u00e5nd der giver injektion i l\u00e5ret.\" class=\"wp-image-28094\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo10.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Phesgo gives udelukkende som indspr\u00f8jtning under huden (subkutant), altid i l\u00e5ret.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Startdosis:<\/strong> 1200 mg pertuzumab \/ 600 mg trastuzumab. Indspr\u00f8jtningen tager 1. gang ca. 8 minutter. Herefter 5 minutter. [8, 9]<\/li>\n\n\n\n<li><strong>Vedligeholdelsesdosis:<\/strong> 600 mg pertuzumab \/ 600 mg trastuzumab. Indspr\u00f8jtningen tager ca. 5 minutter.<\/li>\n\n\n\n<li><strong>Observation:<\/strong> Efter injektionen skal patienten observeres for allergiske reaktioner (30 min. f\u00f8rste gang, 15 min. efterf\u00f8lgende).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Kan man undg\u00e5 kemoterapi? <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Standardbehandlingen er at kombinere Phesgo med kemoterapi (taxaner) for at sl\u00e5 sygdommen h\u00e5rdest muligt ned. Men nyere data (fra PERNETTA-studiet) viser en alternativ vej for patienter, der \u00f8nsker at undg\u00e5 kemoterapiens bivirkninger. Ved kun at give antistofferne (Phesgo) opn\u00e5r man en &#8220;kemo-fri&#8221; behandling.  [4, 5]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dilemmaet ved denne strategi er tydeligt i tallene:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Uden kemo:<\/strong> Sygdommen holdes i ro i kortere tid (kortere progressionsfri overlevelse), f\u00f8r den begynder at vokse igen.<\/li>\n\n\n\n<li><strong>Med kemo:<\/strong> Sygdommen holdes i ro l\u00e6ngere tid (ca. 23 mdr. vs. 8,4 mdr.).<\/li>\n\n\n\n<li><strong>MEN \u2013 samlet overlevelse:<\/strong> Den totale overlevelse efter 2 \u00e5r er stort set ens for begge grupper (ca. 78-79%).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Det betyder, at man kan starte &#8220;mildt&#8221; uden kemo. Hvis kr\u00e6ften blusser op, kan man skifte spor (f.eks. til T-DM1), uden at det ser ud til at koste p\u00e5 den lange bane. Dette er is\u00e6r relevant for \u00e6ldre eller sv\u00e6kkede patienter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bivirkninger\"><\/span>Bivirkninger<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-150x150.jpg\" alt=\"Phesgo symboliseret ved en sk\u00e6rm med rosa kr\u00e6ftceller, et h\u00e6tteglas med phesgo og et mikroskop\" class=\"wp-image-28096\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo8.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Sikkerhedsprofilen for Phesgo svarer til den, man kender fra intraven\u00f8s behandling. Hvis man v\u00e6lger den kemo-frie strategi, undg\u00e5r man mange af de nedenst\u00e5ende bivirkninger (som neutropeni og nerveskader), der prim\u00e6rt skyldes kemoterapien.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Hjertep\u00e5virkning<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Dette er den mest alvorlige risiko ved selve antistofferne. HER2-receptorer findes ogs\u00e5 p\u00e5 raske hjerteceller. N\u00e5r behandlingen blokerer disse, kan hjertemusklens evne til at tr\u00e6kke sig sammen sv\u00e6kkes.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Symptomer:<\/strong> Mange m\u00e6rker intet i starten, men det kan udvikle sig til symptomatisk hjertesvigt med \u00e5nden\u00f8d ved anstrengelse, hoste om natten og h\u00e6vede ankler (\u00f8demer).<\/li>\n\n\n\n<li><strong>Konsekvens:<\/strong> Behandlingen m\u00e5 ofte pauseres eller stoppes helt, hvis pumpefunktionen falder under en vis gr\u00e6nse (typisk 50%).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Mave-tarm-systemet<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diarr\u00e9:<\/strong> Pertuzumab-komponenten er kendt for at give sv\u00e6r diarr\u00e9 hos over 60% af patienterne. Det kan variere fra lette tilf\u00e6lde til alvorlig dehydrering, der kr\u00e6ver hospitalsindl\u00e6ggelse. Det opst\u00e5r ofte tidligt i forl\u00f8bet.<\/li>\n\n\n\n<li><strong>Slimhindebet\u00e6ndelse (mucositis):<\/strong> S\u00e5r i munden, smagsforstyrrelser og mavesmerter er almindeligt.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Blod og immunforsvar<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Febril neutropeni:<\/strong> En farlig tilstand, hvor antallet af hvide blodlegemer dykker kritisk lavt samtidig med feber. Det betyder, at kroppen ikke kan bek\u00e6mpe infektioner. Det kr\u00e6ver akut indl\u00e6ggelse. <em>Bem\u00e6rk:<\/em> Denne risiko er markant lavere, hvis man frav\u00e6lger den samtidige kemoterapi. [4]<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Lokale reaktioner (injektionsstedet) <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Da en stor m\u00e6ngde v\u00e6ske tvinges ind i v\u00e6vet, oplever ca. 15-20% gener ved indstiksstedet i l\u00e5ret.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Symptomer:<\/strong> Smerter, r\u00f8dme, blodudtr\u00e6dninger (h\u00e6matom) og h\u00e6velse. Det er typisk forbig\u00e5ende.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Statistikker_og_evidens\"><\/span>Statistikker og evidens<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-150x150.jpg\" alt=\"Phesgo symboliseret ved en pc-sk\u00e6rm med s\u00f8jlediagrammer i bl\u00e5 og rosa.\" class=\"wp-image-28104\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-600x601.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a-768x769.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo2a.jpg 849w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Phesgo er godkendt p\u00e5 baggrund af studier, der viser, at det virker lige s\u00e5 godt som den gamle behandling, samt at patienterne foretr\u00e6kker det.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Effekt<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">FeDeriCa-fase 3-studiet sammenlignede Phesgo med intraven\u00f8s Pertuzumab+Trastuzumab hos 500 patienter.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Resultat:<\/strong> Patologisk komplet respons (pCR), som er m\u00e5let for, om kr\u00e6ften er helt v\u00e6k ved operationen, var 59,7% for Phesgo mod 59,5% for den intraven\u00f8se gruppe. Effekten er alts\u00e5 identisk. [1]<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Patientpr\u00e6ference<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">I PHranceSCa-studiet fik 160 patienter lov at pr\u00f8ve begge behandlingsformer og skulle derefter v\u00e6lge.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Resultat:<\/strong> 85% af patienterne foretrak Phesgo (injektion) frem for drop. [2, 3]<\/li>\n\n\n\n<li><strong>Begrundelse:<\/strong> Tidsbesparelse p\u00e5 hospitalet og frav\u00e6r af n\u00e5l i blod\u00e5ren.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Konklusion\"><\/span>Konklusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-150x150.jpg\" alt=\"Phesgo symboliseret ved en kvindelig l\u00e6ge i hvid kittel der taler med en kvindelig patient. Et bord og en pc er imellem dem.\" class=\"wp-image-28103\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2026\/01\/Phesgo1.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Phesgo repr\u00e6senterer et v\u00e6sentligt praktisk fremskridt i behandlingen af HER2-positiv brystkr\u00e6ft. Ved at konvertere en langvarig drop-behandling til en hurtig indspr\u00f8jtning, sparer patienterne tid uden at g\u00e5 p\u00e5 kompromis med effekten mod kr\u00e6ften. Dette understreges af, at langt de fleste patienter foretr\u00e6kker denne l\u00f8sning. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Samtidig \u00e5bner ny forskning op for, at visse patienter kan behandles effektivt med Phesgo uden samtidig kemoterapi, hvilket kan sk\u00e5ne dem for mange bivirkninger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det er dog afg\u00f8rende at huske, at Phesgo fortsat er kraftig medicin, der kr\u00e6ver t\u00e6t overv\u00e5gning af is\u00e6r hjertets funktion.<\/p>\n\n\n\n<p class=\"has-custom-menu-links-color has-text-color has-link-color wp-elements-78958270cc4840b7bdca48105c79180e wp-block-paragraph\"><strong><a href=\"#menu\" data-type=\"internal\" data-id=\"#diagnose\">(Til menu)<\/a><\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Links<\/h4>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-e970b01b1e068005630d79cbe982ae74 wp-block-paragraph\">[1] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33357420\/\" target=\"_blank\" rel=\"noopener\">Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer<\/a> (FeDeriCa) (PubMed, 2021)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Det prim\u00e6re studie (FeDeriCa) publiceret i The Lancet Oncology. Det dokumenterer, at Phesgo giver samme effekt p\u00e5 kr\u00e6ftknuden (pCR) og samme m\u00e6ngde medicin i blodet som den traditionelle behandling i drop. <\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-a9eeac77c092ba8997f824eae57b52e6 wp-block-paragraph\">[2] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34147014\/\" target=\"_blank\" rel=\"noopener\">Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PHranceSCa)<\/a> (PubMed, 2021)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Data fra PHranceSCa-studiet, der dokumenterer, at over 80% af patienterne foretr\u00e6kker den subkutane injektion (Phesgo) frem for intraven\u00f8s behandling, prim\u00e6rt p\u00e5 grund af den reducerede tid p\u00e5 hospitalet.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-e037045bcb8d74b8dc91b7047857feae wp-block-paragraph\">[3] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33907384\/\" target=\"_blank\" rel=\"noopener\">Patient Preference for Subcutaneous vs Intravenous Administration<\/a> (The ASCO Post, 2020) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> En mere letl\u00e6selig artikel fra den store amerikanske kr\u00e6ftkongres, der gennemg\u00e5r patienternes oplevelse og hvorfor de v\u00e6lger indspr\u00f8jtningen.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-6e5f6e781aa4fcc0f4299c12b1bcd87e wp-block-paragraph\">[4] <a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2808225\" target=\"_blank\" rel=\"noopener\">Pertuzumab Plus Trastuzumab With or Without Chemotherapy<\/a> (JAMA Oncology, 2023) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Analyse af PERNETTA-studiet, der viser, at en sk\u00e5nsom strategi uden kemoterapi (kun antistoffer) kan v\u00e6re en mulighed for visse patienter, uden at det g\u00e5r ud over den samlede overlevelse.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-b9a9e14446b7453c31b3ca802cc70aab wp-block-paragraph\">[5] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36716289\/\" target=\"_blank\" rel=\"noopener\">Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive Metastatic Breast Cancer (PERTAIN Final Analysis)<\/a> (PubMed, 2023)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Den endelige analyse af PERTAIN-studiet, der bekr\u00e6fter, at kombinationen af pertuzumab, trastuzumab og en aromataseh\u00e6mmer er effektiv og sikker, hvilket st\u00f8tter strategien om behandling uden kemoterapi for udvalgte patienter.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-a5ebb334af1061c87d556881064b9930 wp-block-paragraph\">[6] <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1113216\" target=\"_blank\" rel=\"noopener\">Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (CLEOPATRA)<\/a> (New England Journal of Medicine, 2015) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Det fundamentale studie, der beviste, at kombinationen af disse to antistoffer (som nu findes i Phesgo) forl\u00e6ngede overlevelsen markant sammenlignet med kun \u00e9t antistof.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-0bbc29c464cf144c7aa4bbed27472ee9 wp-block-paragraph\">[7] <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/phesgo\" target=\"_blank\" rel=\"noopener\">Phesgo | European Medicines Agency (EMA)<\/a> (European Medicines Agency, 2020)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Den officielle europ\u00e6iske godkendelse (EPAR), der indeholder detaljeret produktinformation, medicinske vurderinger samt data om sikkerhed og effekt.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-a6f53434e003d89e729d374b1ff13db0 wp-block-paragraph\">[8] <a href=\"https:\/\/onkologisktidsskrift.dk\/behandlinger\/brystkraeft\/3721-phesgo-anbefalet-til-brug-uden-for-hospitalet-ved-her2-positiv-brystkraeft.html\" target=\"_blank\" rel=\"noopener\">Phesgo anbefalet til brug uden for hospitalet ved HER2-positiv brystkr\u00e6ft<\/a> (Onkologisk Tidsskrift, 2025)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Artikel der beskriver Medicinr\u00e5dets anbefaling af Phesgo. Anbefalingen begrundes med, at den enkle indspr\u00f8jtning frig\u00f8r ressourcer p\u00e5 sygehusene og g\u00f8r det muligt at tilbyde patienterne behandling t\u00e6ttere p\u00e5 eget hjem.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-afee5ee8e3d3c3ae376cdf8c6ff6f9bb wp-block-paragraph\">[9] <a href=\"https:\/\/pro.medicin.dk\/Medicin\/Praeparater\/9711\" target=\"_blank\" rel=\"noopener\">Phesgo <\/a>(Medicin.dk, 2026)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indhold:<\/strong> Database for sundhedspersonale. Siden indeholder de komplette tekniske data, herunder detaljerede bivirkningslister, kontraindikationer, interaktioner med anden medicin samt pr\u00e6cise instrukser for dosering og sporbarhed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siden oprettet:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">d. 11.01.26<a href=\"https:\/\/jegharkraeft.dk\/dr-vogl\"><\/a><\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-menu-links-color\">\u2764<\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hvad du l\u00e6ser p\u00e5 <\/strong><em><strong>Jeg har Kr\u00e6ft<\/strong><\/em><strong> er ikke en anbefaling. S\u00f8g kompetent vejledning.<\/strong><\/p>\n<\/div>\n<\/div>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Indhold<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Behandlinger\" >Behandlinger<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Phesgo_mod_kraeft\" >Phesgo mod kr\u00e6ft<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Hvad_er_Phesgo\" >Hvad er Phesgo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Hvordan_virker_det\" >Hvordan virker det<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Sadan_foregar_behandlingen\" >S\u00e5dan foreg\u00e5r behandlingen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Bivirkninger\" >Bivirkninger<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Statistikker_og_evidens\" >Statistikker og evidens<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/jegharkraeft.dk\/en\/phesgo\/#Konklusion\" >Konklusion<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Behandlinger Traditionelle Behandlinger Oversigt 0. Traditionelle Behandlinger Alment Phesgo mod kr\u00e6ft Resum\u00e9 om Phesgo Sammens\u00e6tning: Indikation: Administration: Ny viden: Hvad er Phesgo M\u00e5lrettet Phesgo er et m\u00e5lrettet middel, der fungerer som en intelligent m\u00e5ls\u00f8gende robot. I mods\u00e6tning til traditionel kemoterapi, der angriber alle celler, der deler sig hurtigt, genkender Phesgo helt specifikt de HER2-proteiner, som [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":28097,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[150,18,143,22],"tags":[],"class_list":["post-28081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-maalrettet-terapi","category-behandlinger","category-laegemiddelbehandling","category-traditionelle-behandlinger"],"modified_by":"Hanne","wpml_current_locale":"da_DK","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/28081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/comments?post=28081"}],"version-history":[{"count":0,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/28081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media\/28097"}],"wp:attachment":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media?parent=28081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/categories?post=28081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/tags?post=28081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}